Physician profile
Royce E Dunn
NPI 1841243086
$375.31
in general payments reported to CMS, 2019-2025
13 companies · $77.97 in 2025
The $77.97 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $120 · 2024: $177 · 2025: $77.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80.22 | 2023-2024 | |
| Amgen INC. | $36.56 | 2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.43 | 2024 | Ofev |
| Abbvie INC. | $34.78 | 2023-2024 | Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $28.32 | 2023-2024 | Breztri |
| Astellas Pharma US INC | $24.73 | 2023 | Veozah |
| Amneal Pharmaceuticals LLC | $24.02 | 2024 | Unithroid |
| Axsome Therapeutics, INC. | $21.07 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $20.60 | 2023 | |
| Novo Nordisk INC | $20.34 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $19.99 | 2024 | Injectafer |
| Tolmar, INC. | $14.91 | 2024 | |
| Lilly USA, LLC | $13.34 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Royce Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.